Key result
Low exercise capacity linked to ~223% higher 5-year mortality in HeartMate 3 LVAD recipients.
Why the study?
Peak oxygen uptake is a validated prognostic marker in advanced HF, but its value in contemporary LVAD recipients is uncertain.
Does peak oxygen uptake predict long-term clinical outcomes in fully magnetically levitated left ventricular assist device recipients?
Cohort (n=250)
Yes
Does peak oxygen uptake predict long-term clinical outcomes in fully magnetically levitated left ventricular assist device recipients?
Answers are grounded in this paper and cite their sources.
Peak oxygen uptake is a strong predictor of long-term mortality and heart failure recurrence in contemporary LVAD recipients, supporting the use of cardiopulmonary exercise testing for risk stratification.
Peak oxygen uptake (pVO 2 ) is a validated prognostic marker in advanced heart failure (HF), but its value in contemporary recipients of left ventricular assist devices (LVAD) is uncertain. We assessed whether pVO 2 predicts long-term clinical outcomes in a cohort of exclusively HeartMate 3 recipients. We retrospectively studied 250 recipients at two European centers (2015–2025) who completed cardiopulmonary exercise testing 90–400 days postimplant. The median age was 56.7 years, 29% were female, and the median pVO 2 was 13.0 (10.7–16.8) ml/kg/min. Low pVO 2 (≤12 ml/kg/min on β-blocker or ≤14 off) was observed in 52%. During a median follow-up of 770 days, low pVO 2 was associated with inferior 5-year overall survival (57% vs . 84%; hazard ratio [HR], 3.23; 95% confidence interval [CI], 1.49–7.14) and survival free from heart failure recurrence (44% vs . 78%; HR, 3.13; 95% CI, 1.69–5.88). Each 1 ml/kg/min increase in pVO 2 reduced the hazard of death or HF recurrence by 16% ( p < 0.001). Low pVO 2 was also associated with a greater hospitalization burden and more ventricular arrhythmias, but no association with hemocompatibility-related adverse events. In contemporary LVAD recipients, pVO 2 predicts mortality and clinically relevant nonmortality outcomes, supporting cardiopulmonary exercise testing for long-term risk stratification and management in stable LVAD patients.
No takes yet. Share an insight, caveat, or question.
Nielsen et al. (2026) conducted a cohort in Advanced heart failure (n=250). Low peak oxygen uptake (pVO2) vs. Higher peak oxygen uptake was evaluated on 5-year overall survival (HR 3.23, 95% CI 1.49-7.14). Low exercise capacity in HeartMate 3 LVAD recipients was associated with inferior 5-year overall survival compared to higher uptake.
Synapse has enriched 10 related papers. Consider them for comparative context: